Skip to main content
Robert Schooley, MD, Infectious Disease, La Jolla, CA, UC San Diego Medical Center - Hillcrest

RobertTurnerSchooleyMD

Infectious Disease • La Jolla, CA

HIV/AIDS Medicine, International Health, Travel & Tropical

Professor, Medicine, UCSD School of Medicine

Join to view full profile

Dr. Schooley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schooley's full profile

Already have an account?

  • Office

    University of California San Diego
    Student Services Center, Mail Stop 0003
    La Jolla, CA 92093
    Phone+1 858-246-2693
  • Is this information wrong?

Education & Training

  • Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School
    Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1979 - 1981
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1976 - 1979
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
  • Johns Hopkins University
    Johns Hopkins UniversityInternship, Internal Medicine, 1974 - 1975
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1974
  • Washington and Lee University
    Washington and Lee UniversityBS, 1970

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 1990 - 2025
  • CA State Medical License
    CA State Medical License 2005 - 2024
  • MD State Medical License
    MD State Medical License 1974 - 1983
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Who's Who in America 1995-2018
  • Gold Doc Arnold P. Gold Foundation, 2009
  • Chief Residents’ Clinical Teaching University of California, San Diego, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Successful Treatment of Antibiotic Resistant Poly-Microbial Bone Infection with Bacteriophages and Antibiotics Combination  
    Robert Schooley, MD, Clinical Infectious Diseases
  • Oa the Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and Mozambique  
    Robert Schooley, MD, The American Journal of Tropical Medicine and Hygiene
  • The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
    Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
  • Join now to see all

Books/Book Chapters

  • AIDS and Other Manifestations of HIV Infection. 
    Chapter: Antiretroviral Chemotherapy 
    Page 827 - 840Schooley RTEditors: G.P. Wormser.Raven Press, New YorkEdition 4,
  • Mechanisms of Microbial Diseases. 
    Chapter: Human Retroviruses: AIDS and Other Diseases 
    Page 376 - 388Schooley RTEditors: Engleberg NC, DiRita V and Dermody TS.Lippincott Williams and WilkinsEdition 4,
  • Cecil’s Textbook of Internal Medicine. 
    Chapter: Epstein Barr Virus Infection 
    Schooley RT
  • Join now to see all

Abstracts/Posters

  • Long-term propagation of New World primate T-lymphocytes in vitro.
    Falk Jr. LA, Silva D, Byington R and Schooley RT, Fifteenth International Leukocyte Culture Conference. Intercell Communicat in Leucocyte Function

Other

  • Therapeutic decision making in 1997. 
    Cotton D, Bartlett J, Schooley R, Gulick R
  • Check, but not checkmate. 
    Schooley RT, Antiviral Therapy. 1997; 2:68-9
  • Antiretroviral chemotherapy. 
    Saag MS and Schooley RT, Curr Clin Top Infect Dis. 1998; 18:154- 79
  • Join now to see all

Press Mentions

  • Outbreak of Eyedrop-Linked Bacteria Kills Three, CDC Reports
    Outbreak of Eyedrop-Linked Bacteria Kills Three, CDC ReportsMarch 22nd, 2023
  • After Dozens of Children at Local Hospital Test Positive for Bacteria, Tap Water Found to Be the Source
    After Dozens of Children at Local Hospital Test Positive for Bacteria, Tap Water Found to Be the SourceDecember 9th, 2022
  • Researchers Use Genetic Sequencing and Wastewater Analysis to Detect SARS-CoV-2 Variants and Monkeypox Within Communities
    Researchers Use Genetic Sequencing and Wastewater Analysis to Detect SARS-CoV-2 Variants and Monkeypox Within CommunitiesSeptember 12th, 2022
  • Join now to see all

Grant Support

  • Orally Active Nucleoside Phosphonates For Hepatitis C VirusNational Institute Of Allergy And Infectious Diseases2009–2012
  • Multiplex Nucleic Acid Detection Devices For The Diagnosis Of Respiratory VirusesNational Institute Of Allergy And Infectious Diseases2007–2011
  • International ProgramNational Institute Of Allergy And Infectious Diseases2006–2011
  • Research In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2005–2011
  • Biochip Diagnostic Tool For Bt Induced DiseasesNational Institute Of Allergy And Infectious Diseases2005–2007
  • The Role Of Sex And HCV Co-Infection In HIV TherapyNational Institute Of Allergy And Infectious Diseases2004
  • ACTG A5116:2 Regimen Trial For HIV SubjectsNational Center For Research Resources2004
  • U Of Colorado Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2003–2004
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2003
  • Colorado Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2000–2003
  • University Of Colorado HIV Research Training ProgramNational Institute Of Allergy And Infectious Diseases1992–2003
  • Subcutaneous IL-2 In Combination With HaartNational Center For Research Resources2000–2002
  • Dynamics Of HCV Infection During Antiretroviral TherapyNational Center For Research Resources2000–2002
  • Chemotherapy/Immunotherapy For HIV InfectionNational Center For Research Resources2000–2002
  • Soft Gelatin Capsule Of Saquinavir In Comb WI Ritonavir Or NelfinavirNational Center For Research Resources1999–2002
  • Phase III Trial:Efavirenz/ Nelfinavir In Combination WI Lamivudine/ZidovudineNational Center For Research Resources1999–2002
  • Phase II Stdy Indinavir+Nevirapine+Stavudine In Subj Prev Trtd W/ 141w94/Vx-478National Center For Research Resources1999–2002
  • Phase II Prolong Virologic Success &Optn For Failure In HIV Sub On IndinavirNational Center For Research Resources1999–2002
  • Actg384 Protease Inhibitor &/Or NON Nucleoside Reverse Trans InhibitorNational Center For Research Resources1999–2002
  • ACTG 398, Phase II Trial Of Amprenavir As PART Of Dual Protease InhibNational Center For Research Resources1999–2002
  • ACTG 362 Trials Of Azithromycin Prophylaxis To Prevent MAC DiseaseNational Center For Research Resources1999–2002
  • ACTG 323 Fluconazole As Therapy For Oropharyngeal CandidiasisNational Center For Research Resources1999–2002
  • A5025 Phase II Random Study Of Hydroxyurea In Subj On Potent AntiretroviralsNational Center For Research Resources1999–2002
  • Actg368 Indinavir Sulfate, Dmp266 &1592u89 In HIV Infected SubjectsNational Center For Research Resources1998–2002
  • 3 Maintenence Regimens For HIV Subjects REC Zidovudine, Lamivudine, IndinavirNational Center For Research Resources1998–2002
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases1997–2002
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1999–2001
  • Actg347 Phase II Study Of 141w94/Vx478 Monotherapy VS 141w94/Vx + ZidovudineNational Center For Research Resources1998–2000
  • Virologic Responses To New Nucleoside Regimens After ZDV Or DDI MonotherapyNational Center For Research Resources1997–2000
  • Influence Of Risk Status For Disease Progression On The Response To InterventionNational Center For Research Resources1997–2000
  • ACTG 320 Phase III Indinavir SulfateNational Center For Research Resources1997–2000
  • ACTG 315 Ritonavir, Zidovudine And Lamivudine In Advanced HIV 1 DiseaseNational Center For Research Resources1997–2000
  • ACTG 285 Stem Cell Mobilization And Harvesting With FilgrastimNational Center For Research Resources1997–2000
  • Safety, Tolerability And Pharmacokinetics Of Thalidomide In HIV1 PatientsNational Center For Research Resources1998–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Zdv/Ddi Regimens On Measures Of Viral Burden In Early HIV-1 InfectionNational Center For Research Resources1997–1999
  • Phase II/III Double-Blind Study Of Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources1997–1999
  • Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1997–1999
  • D4T VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Infected PatientsNational Center For Research Resources1997–1999
  • ACTG 333--Hard Capsule And Soft Capsule Saquinavir VS IndinavirNational Center For Research Resources1997–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–1999
  • Dapsone And Atovaquone Study For PCP In HIV Infected PatientsNational Center For Research Resources1996–1999
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1996–1998
  • Trial To Evaluate Activity Of 141W94 In Patients With HIV InfectionNational Center For Research Resources1997
  • Random Dbl-Bld, Combination Of Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1997
  • Phase I/II Open-Label Trial Of Delavirdine Mesylate (Dlv, U-90152s)National Center For Research Resources1997
  • Evaluation Of STD Therapy VS STD Therapy W/Msl 109 In AIDS Patients W/CmvNational Center For Research Resources1997
  • Delavirdine And ZDV Or Didanosine VS ZDV And DDI Combination TherapyNational Center For Research Resources1997
  • 1592U89 Alone And With Retrovir For HIV Infection (Glaxo/Wellcome (131-002)National Center For Research Resources1997
  • Phase II/III Clarithromycin Regimens For MAC In HIV Positive PatientsNational Center For Research Resources1996–1997
  • HIV-1 Derived Immunogens In Infected Individuals W/500 CD4 Cells/Mm3National Center For Research Resources1996–1997
  • ACTG 175--Monotherapy VS Combination Therapy In HIV PTS, CD4 200-500National Center For Research Resources1996–1997
  • Conference On Immunopathogenesis Of HIV InfectionNational Institute Of Allergy And Infectious Diseases1996
  • Short Term Clinical And Virologic Significance Of ZDV ResistanceNational Center For Research Resources1996
  • ACTG 303--Influence Of Risk Status For Disease ProgressionNational Center For Research Resources1996
  • ACTG 290-D4t VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Positive PatientsNational Center For Research Resources1996
  • ACTG 276--Various Zdv/Ddi Regimens On Measures Of Viral BurdenNational Center For Research Resources1996
  • ACTG 261--Delavirdine And ZDV VS ZDV And DDI Combination TherapyNational Center For Research Resources1996
  • ACTG 260--Phase I/II Trial Of Delavirdine MesylateNational Center For Research Resources1996
  • ACTG 259--Phase II SC 49483 With ZDV Versus ZDVNational Center For Research Resources1996
  • ACTG 248--Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1996
  • ACTG 241--Ddi PLUS Nevirapine Versus ZDV PLUS DDINational Center For Research Resources1996
  • ACTG 209--Phase I/II Trial Vaccine Therapy In HIV1 Infected IndividualsNational Center For Research Resources1996
  • ACTG 206--Alpha Interferon With DDI For Patients With Kaposis SarcomaNational Center For Research Resources1996
  • ACTG 204a--Valacyclovir Hydrocholoride Study In HIV Positive PatientsNational Center For Research Resources1996
  • ACTG 193a--Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1996
  • 1592U89 Alone And With Retrovir For HIV InfectionNational Center For Research Resources1996
  • Ribozymes As Molecular Therapies For AIDSNational Institute Of Allergy And Infectious Diseases1994–1996
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
  • Cell Mediated Immune Response To Human RetrovirusesNational Cancer Institute1990–1994
  • Colorado AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
  • AIDS &Related Research 1 Study SectionCenter For Scientific Review1990
  • Cellular Immune Response To HIVNational Cancer Institute1987–1989
  • Human T-Cell Leukemia Virus--Virus-Host InteractionsNational Cancer Institute1985–1986

Committees

  • Chair, NIH Drug Discovery and Resistance (DDR) Study Section 2011 - 2013
  • Member, Scientific Advisory Board, PEPFAR, US Department of State 2011 - 2013

Hospital Affiliations

Dr. Robert Schooley, Dr. Robert Schooley, MD, Dr. R Schooley, Dr. Robert Turner Schooley